GangaGen (Ottawa, Ontario, Canada, www.gangagen.com), a firm developing bacteriophage technology for treating antibiotic-resistant bacterial infections, has received a new US patent. It is for the invention of "Lysin-deficient bacteriophages having reduced immunogenicity," to be used to destroy pathenogenic bacteria. The patent is a major step in developing phages for use as systemic therapeutics in human and veterinary medicine.
Bacteriophages, or "phages" are naturally occurring agents that target and destroy bacteria selectively. Some believe they could possibly treat bacterial infections because they would not affect beneficial bacteria or tissue cells. They also have the capability of evolving as bacteria do, possibly avoiding bacterial resistance to antibiotics.
Комментариев нет:
Отправить комментарий